Open‐Label Study Assessing Relative and Absolute Bioavailability of Oral Camizestrant Formulations and Food Effects in Healthy Postmenopausal Women
Authors:
- Andy SykesASAndy Sykes
- Helena EngmanHEHelena Engman
- Nigel TaylorNTNigel Taylor
- Tim BrierTBTim Brier
- Rhiannon MaudsleyRMRhiannon Maudsley
- Bistra KirovaBKBistra Kirova
- Alastair M. MathewsonAMAlastair M. Mathewson
- Ryan A. BraggRBRyan A. Bragg
- Eric T. GanglEGEric T. Gangl
- Teresa KlinowskaTKTeresa Klinowska
- Yan LiYLYan Li
Open Access
- 20 January 2026
- journal article
- research article
- Published by Wiley in Clinical and Translational Science
- Vol. 19 (2) , e70475
Abstract
Camizestrant is the next‐generation oral selective estrogen receptor degrader and complete estrogen receptor antagonist in Phase 3 development for hormone receptor‐positive breast cancer. To investigate the impact of manufacturing changes during pivotal Phase 3 studies, this open‐label, randomized crossover study of 32 postmenopausal healthy volunteers determined the relative bioavailability of a tablet used in early clinical studies (Phase 1 tablet), a tablet designed for late‐phase development (prototype Phase 3 tablet), and an oral solution. Absolute oral bioavailability in the fasted state (using a [ 14 C] camizestrant intravenous microtracer) and effects of a high‐fat meal on the prototype Phase 3 tablet were also determined. The geometric mean ratios (GMRs) of the prototype Phase 3/Phase 1 tablets (% [90% CI]) for C max and AUC, respectively were 98.7 (87.4–111.5) and 97.4 (92.6–102.5) at 75 mg ( n = 15), and 96.6 (86.9–107.5) and 100.4 (96.2–104.9) at 300 mg ( n = 15). GMRs of the prototype Phase 3 tablet/oral solution for C max and AUC were 96.2 (85.3–108.7) and 99.5 (94.6–104.6) at 75 mg ( n = 15). Fed‐to‐fasted C max and AUC GMRs were 106.2 (94.3–119.7) ( n = 16) and 109.8 (104.4–115.5) ( n = 15) at 75 mg ( n = 16), and 115.9 (104.3–128.7) and 102.3 (98.0–106.8) at 300 mg ( n = 15). Absolute oral bioavailability at 75 mg ( n = 6) and 300 mg ( n = 6) was 42.5% (36.8%–49.0%) and 55.1% (48.5%–62.5%). The formulations showed similar exposures, supporting the planned manufacturing changes. Camizestrant exhibited moderate bioavailability; exposures were similar under fasted and high‐fat meal conditions, supporting its administration with or without food.Keywords
This publication has 16 references indexed in Scilit:
- A phase I dose escalation and expansion trial of the next-generation oral SERD camizestrant in women with ER-positive, HER2-negative advanced breast cancer: SERENA-1 monotherapy resultsAnnals of Oncology, 2024
- Discovery of AZD9833, a Potent and Orally Bioavailable Selective Estrogen Receptor Degrader and AntagonistJournal of Medicinal Chemistry, 2020
- A Randomized, Open-label, Presurgical, Window-of-Opportunity Study Comparing the Pharmacodynamic Effects of the Novel Oral SERD AZD9496 with Fulvestrant in Patients with Newly Diagnosed ER+ HER2− Primary Breast CancerClinical Cancer Research, 2020
- A Phase 1, Open-Label Study in Healthy Subjects to Evaluate the Absolute Bioavailability of AG-221 by a Microtracer ApproachOncology and Therapy, 2019
- Evolution of Targeted Therapy in Breast Cancer: Where Precision Medicine BeganAmerican Society of Clinical Oncology Educational Book, 2018
- Novel Application of the Two‐Period Microtracer Approach to Determine Absolute Oral Bioavailability and Fraction Absorbed of ErtugliflozinClinical and Translational Science, 2018
- Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized ‘FIRST’ studyBreast Cancer Research and Treatment, 2012
- Patients' preference for administration of endocrine treatments by injection or tablets: results from a study of women with breast cancerAnnals of Oncology, 2005
- Fulvestrant: pharmacokinetics and pharmacologyBritish Journal of Cancer, 2004
- ICI 182,780 (Fulvestrant)--the first oestrogen receptor down-regulator--current clinical data.2001